Epilepsy Syndromes, Etiologies, and the Use of Next-generation Sequencing in Epilepsy Presenting in the First 2 Years of Life: A Population-based Study
Authors
Affiliations
Objective: Population-based data on epilepsy syndromes and etiologies in early onset epilepsy are scarce. The use of next-generation sequencing (NGS) has hitherto not been reported in this context. The aim of this study is to describe children with epilepsy onset before 2 years of age, and to explore to what degree whole exome and whole genome sequencing (WES/WGS) can help reveal a molecular genetic diagnosis.
Methods: Children presenting with a first unprovoked epileptic seizure before age 2 years and registered in the Stockholm Incidence Registry of Epilepsy (SIRE) between September 1, 2001 and December 31, 2006, were retrieved and their medical records up to age 7 years reviewed. Children who met the epilepsy criteria were included in the study cohort. WES/WGS was offered in cases of suspected genetic etiology regardless of whether a structural or metabolic diagnosis had been established.
Results: One hundred sixteen children were included, of which 88 had seizure onset during the first year of life and 28 during the second, corresponding to incidences of 139 and 42/100 000 person-years, respectively. An epilepsy syndrome could be diagnosed in 54% of cases, corresponding to a birth prevalence of 1/1100. Structural etiology was revealed in 34% of cases, a genetic cause in 20%, and altogether etiology was known in 65% of children. The highest diagnostic yield was seen in magnetic resonance imaging (MRI) with 65% revealing an etiology. WES/WGS was performed in 26/116 cases (22%), with a diagnostic yield of 58%.
Significance: Epilepsy syndromes can be diagnosed and etiologies revealed in a majority of early onset cases. NGS can identify a molecular diagnosis in a substantial number of children, and should be included in the work-up, especially in cases of epileptic encephalopathy, cerebral malformation, or metabolic disease without molecular diagnosis. A genetic diagnosis is essential to genetic counselling, prenatal diagnostics, and precision therapy.
Developmental and epileptic encephalopathies.
Scheffer I, Zuberi S, Mefford H, Guerrini R, McTague A Nat Rev Dis Primers. 2024; 10(1):61.
PMID: 39237642 DOI: 10.1038/s41572-024-00546-6.
Jonsson H, Gaily E, Stjerna S, Joensuu T, Johari M, Lehesjoki A Epilepsia Open. 2024; 9(4):1393-1405.
PMID: 38785332 PMC: 11296082. DOI: 10.1002/epi4.12966.
Bayanova M, Bolatov A, Bazenova A, Nazarova L, Nauryzbayeva A, Tanko N Mol Neurobiol. 2023; 60(8):4324-4335.
PMID: 37095367 PMC: 10293429. DOI: 10.1007/s12035-023-03346-3.
Nine patients with KCNQ2-related neonatal seizures and functional studies of two missense variants.
Chokvithaya S, Caengprasath N, Buasong A, Jantasuwan S, Santawong K, Leela-Adisorn N Sci Rep. 2023; 13(1):3328.
PMID: 36849527 PMC: 9971330. DOI: 10.1038/s41598-023-29924-y.
Clinical and Neurophysiologic Phenotypes in Neonates With Encephalopathy.
Carapancea E, Cornet M, Milh M, De Cosmo L, Huang E, Granata T Neurology. 2023; 100(12):e1234-e1247.
PMID: 36599696 PMC: 10033164. DOI: 10.1212/WNL.0000000000206755.